StockNews.AI
RPRX
StockNews.AI
203 days

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

1. Royalty Pharma will report Q4 and full year 2024 results on February 11. 2. The company is the largest buyer of biopharmaceutical royalties. 3. Royalty Pharma's portfolio includes royalties from over 35 commercial products. 4. The firm funds innovation in biopharma through partnerships and royalty acquisitions. 5. A conference call will be held at 8:30 a.m. ET on the report date.

Earnings
+0.03%Current Return
VS
-0.43%S&P 500
$31.9401/28 04:18 PM EDTEvent Start
$31.9501/29 11:02 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings reports often lead to positive investor sentiment; prior reports have shown growth.

How important is it?

Earnings announcements can significantly influence stock prices; future growth may be highlighted.

Why Short Term?

The immediate impact is felt around earnings announcements, with potential volatility.

Related Companies

VRTXGSKRHHBYJNJBIIBABBVPFEAST
January 28, 2025 16:15 ET  | Source: Royalty Pharma plc NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications +1 (212) 883-6637ir@royaltypharma.com

Related News